Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina.
Department of Neurology, College of Medicine, Medical University of South Carolina.
Neuropsychology. 2024 Sep;38(6):570-588. doi: 10.1037/neu0000952. Epub 2024 Jul 8.
The Memory Binding Test (MBT) shows promise in detecting early cognitive changes associated with Alzheimer's disease (AD). This study assesses the psychometric properties (i.e., construct and criterion validity, test-retest reliability) of the MBT and its sensitivity to incipient disease and incident cognitive impairment.
One hundred forty-nine cognitively unimpaired adults ages 45-85 completed the MBT and neuropsychological tests at baseline; 132 returned for 2-year follow-up. Based on neuroradiological ratings of amyloid positron emission tomography and MRI markers at baseline, they were categorized as healthy ( = 94) or having preclinical disease ( = 55, either on the AD continuum or having non-AD pathologic change). Construct validity was assessed by the associations between MBT scores, demographics, and neuropsychological scores within the healthy group. Criterion validity was assessed by testing how MBT scores correlate with AD biomarkers, differ and discriminate between groups at baseline, and predict incident cognitive impairment.
MBT scores decreased with age and were strongly associated with memory and global cognition. MBT scores were largely not associated with amyloid, hippocampal volume, or AD signature cortical volume but related to white matter lesion volume in those with preclinical disease. The preclinical groups performed worse on MBT immediate free recall at baseline than the healthy group, but no scores predicted incident cognitive impairment at follow-up. Most scores demonstrated modest test-retest reliability.
This study demonstrates that the MBT has adequate construct validity in cognitively unimpaired adults, moderate sensitivity to preclinical disease cross-sectionally, and limited prognostic utility. Careful consideration of demographic influences on score interpretation remains necessary. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
记忆绑定测试（MBT）在检测与阿尔茨海默病（AD）相关的早期认知变化方面显示出前景。本研究评估了 MBT 的心理测量特性（即构念和效标效度、测试-重测信度）及其对疾病初期和认知障碍事件的敏感性。
149 名认知正常的 45-85 岁成年人在基线时完成了 MBT 和神经心理学测试；132 人返回进行了 2 年的随访。根据基线时的正电子发射断层扫描和 MRI 标志物的神经放射学评分，他们被分为健康组（=94）或有临床前疾病组（=55，要么处于 AD 连续体中，要么有非 AD 病理性改变）。构念效度通过健康组内 MBT 评分、人口统计学和神经心理学评分之间的相关性来评估。效标效度通过测试 MBT 评分与 AD 生物标志物的相关性、在基线时与组间的差异和区分度以及预测认知障碍事件来评估。
MBT 评分随年龄下降，与记忆和整体认知密切相关。MBT 评分与淀粉样蛋白、海马体积或 AD 特征性皮质体积基本无关，但与临床前疾病患者的白质病变体积有关。临床前组在基线时的 MBT 即时自由回忆方面的表现明显差于健康组，但没有任何评分在随访时预测认知障碍事件。大多数评分显示出适度的测试-重测信度。
本研究表明，MBT 在认知正常的成年人中具有足够的构念效度，在横截面上对临床前疾病具有中等敏感性，预后效用有限。在解释分数时，仍然需要仔细考虑人口统计学因素的影响。
